Abstract
BackgroundICB have shown remarkable clinical efficacy with durable responses in many cancers. However, many patients are resistant, or develop resistance to ICB. For these patients’ treatment options are limited. Thus,...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
